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Genomics is a relatively new scientific discipline, having DNA sequencing as its core technology. As
technology has improved the cost and scale of genome characterization over sequencing’s 40-year
history, the scope of inquiry has commensurately broadened. Massively parallel sequencing has
proven revolutionary, shifting the paradigm of genomics to address biological questions at a
genome-wide scale. Sequencing now empowers clinical diagnostics and other aspects of medical
care, including disease risk, therapeutic identification, and prenatal testing. This Review explores
the current state of genomics in the massively parallel sequencing era.Prior to the advent of next-generation sequencing (NGS) tech-
nology, genomics initially was concerned with studying
genomes that were tractable from the standpoint of size and
repetitive content (e.g., viruses and bacteria) and with character-
ization of single genes associated with disease (e.g., Cystic
Fibrosis, Huntington disease, and cancer). As the ability to
construct large clone-based physical maps improved, the subcl-
oned fragments of the genome contributing to physical map con-
struction could be sequenced as individual projects, and their
finished sequencesmelded together to represent entire chromo-
somes. Hence, important large genomes, including model or-
ganisms and the human genome, were decoded. Indeed, in
the era of NGS, the short reads obtained from most platforms
absolutely require these reference genomes as a substrate for
read alignment prior to variation discovery. The impact of these
technologies on genomic variant discovery has been profound,
as we will describe. Although we limit the scope of this Review
to genomics, an accompanying Review explores the disruptive
impact of NGS on studies of the epigenome to further highlight
the profound transformation brought on byNGS technology (Riv-
era and Ren, 2013 [this issue of Cell]).
Genomic Techniques
Although NGS technology initially was used to study whole ge-
nomes, a variety of approaches that address defined regions
of the genome have emerged. There are essentially two technical
preparatory approaches to explore selected regions of the
genomewith NGS. The first is by PCR, typically involvingmultiple
primer pairs in a mixture that are combined with genomic DNA of
interest in a multiplex approach to preserve precious DNA. The
use of multiplex primer pairs couples the high throughput of
NGS platforms and the fact that each sequence read represents
a single DNA product in the mixture due to the nature of the
sequencing platforms (Mardis, 2013). Following the PCR, the re-
sulting fragments have platform-specific adapters ligated to their
ends to form a library that is suitable for sequencing. The second
approach involves hybrid capture, which has been developed byseveral groups and commercialized (Albert et al., 2007; Gnirke
et al., 2009; Hodges et al., 2007). Essentially, hybrid capture
takes advantage of the hybridization of DNA fragments from a
whole-genome library to complementary sequences that were
synthesized and combined into a mixture of probes designed
with high specificity for the matching regions in the genome.
These probes typically have covalently linked biotin moieties,
enabling a secondary ‘‘capture’’ by mixing the probe:library
complexes with streptavidin-coated magnetic beads. Hence,
the targeted regions of the genome can be selectively captured
from solution by applying a magnetic field, whereas most of the
remainder of the genome is washed away in the supernatant.
Subsequent denaturation releases the captured library frag-
ments from the beads into solution, ready for postcapture ampli-
fication, quantitation, and sequencing. When the probes are
designed to capture essentially all of the known coding exons
in a genome, the capture approach is referred to as ‘‘exome
sequencing.’’ Additional probes may be designed, synthesized,
and added to an exome reagent, typically referred to as ‘‘exome
plus.’’When only a subset of the exome or of the genome outside
of the exome is targeted, this is called a ‘‘targeted panel.’’
Genomic Analysis
As important as techniques to produce the NGS data that
address biological questions are, analytical approaches are
equally critical for successful interpretation of those data.
Many analytical approaches depend on the digital nature of
NGS data, a consequence of the fact that individual DNA frag-
ments of the library are amplified either on beads or on flat sur-
faces (platform specific) prior to the sequencing reaction. Hence,
each sequence read is equivalent to a single DNA fragment.
What follows are selected data analysis techniques from a
dizzying number of advances published in just the last
18 months. The pace of innovation in analytical approaches to
genome-wide data analysis continues to engage and excite
the computational biology community as the number of technical
applications continues.Cell 155, September 26, 2013 ª2013 Elsevier Inc. 27
Technological advances have often driven the methods for
discovering new disease genes. Early studies leveraged families
in which a diseasewas segregating to identify the genetic causes
of the phenotype. These linkage analysis studies were success-
ful for highly penetrant, monogenic diseases such as cystic
fibrosis. Standard parametric linkage studies of some complex
traits were successful, particularly when sampling from extreme
ends of the phenotypic distribution. For example, analyzing fam-
ilies segregating early onset Alzheimer’s disease led to the dis-
covery of multiple genes that contribute significantly to the
phenotype and shed light on the biological mechanisms (e.g.,
plaque formation) of disease progression (Goate et al., 1991;
Harrington et al., 1995; Pericak-Vance et al., 1991).
Yet, for many complex diseases and traits, this model was not
as successful because the genetic predispositions to complex
traits are, as their name implies, more difficult to elucidate and
require larger numbers of samples to discern signal from noise.
Theoretically, it was determined that comparing allele fre-
quencies across the genome between large numbers of cases
and controls would be able to capture common disease suscep-
tibility alleles (Risch and Merikangas, 1996), and this ushered in
the era of genome-wide association studies (GWAS). It was
economically practical to screen thousands of individuals by
genotyping hundreds of thousands of common single-nucleo-
tide polymorphisms (SNPs) on microarrays. GWAS are well
suited too and have been successful in studying population
structure (Price et al., 2010b), anthropomorphic traits (Berndt
et al., 2013), targets of natural selection such as variants associ-
ated with high-altitude adaptation (Bigham et al., 2009, 2010;
Scheinfeldt et al., 2012), and some complex diseases such as
Crohn’s disease (Yamazaki et al., 2005) and age-related macular
degeneration (Klein et al., 2005). These studies led to hundreds
of replicable associated loci that cannot be fully enumerated in
this Review. GWAS has perhaps had the most impact in the
area of pharmacogenomics, where robust, highly replicable
associations have impacted clinical actions. For example,
warfarin dose is routinely adjusted based upon VKORC1,
CYP2C9, and CYP4F2 genotypes confirmed by GWAS (Takeu-
chi et al., 2009), which has significantly improved patient out-
comes. Yet, most early GWAS yielded few variants with large
effect sizes; this was perhaps to be expected, given the hetero-
geneity of the phenotypes and sample sizes needed to statisti-
cally detect signals of association.
The exponentially decreasing cost of next-generation
sequencing data generation has put large-scale investigation
of rare variation within reach, and there has been a resultant shift
in the field of complex disease genetics over the past 5 years.
GWAS data strongly suggest that the vast majority of the herita-
bility of complex traits will not be due to a few common variants
with low to moderate effects (Schork et al., 2009). Rare variation
with large effect sizes is likely contributing a significant propor-
tion to the ‘‘missing heritability’’ of complex traits and disease
(Cohen et al., 2006; Manolio, 2009; Zhu et al., 2010). The com-
mon disease-common variant versus common disease-rare
variant debate remains unresolved. There are still questions
that remain as to whether the genetic contribution to common
traits can be attributed to an infinite number of common alleles
with small effect, a large number of rare alleles with large effects,28 Cell 155, September 26, 2013 ª2013 Elsevier Inc.or some combination of genes and environment (Gibson, 2011).
But the evaluation of rare variants in common disease is ongoing.
Variant Detection
The advent of NGS has enabled the inquiry of nearly every base
in the genome, and thus techniques to reliably interpret and iden-
tify millions of variants are being developed. As will be described
below, the advantage of sequencing in this regard is that most
variants, common and rare, can be discovered with the appro-
priate sequencing read coverage, algorithmic methods to iden-
tify the variants, and a sufficient careful orthogonal validation
to confirm true from false positives. The exception to this discov-
ery potential is due to the reliance on alignment to the Human
Genome Reference sequence, which is the first step to analysis
of NGS data, as this reference does not contain the entirety of
novel genome content across all humans. Numerous variant-
calling algorithms have been developed for the detection and
genotyping of germline SNPs (DePristo et al., 2011; Koboldt
et al., 2009; Li et al., 2008; McKenna et al., 2010; Shen et al.,
2010) and small indels (Emde et al., 2012; Leone et al., 2013;
Ye et al., 2009) in high-throughput sequencing data. Once de-
tected, these variants can be analyzed in case-control studies
using the same methods that have been developed for GWAS.
Rare Variation and Burden Testing
However, unlike GWAS (which examines common mutations),
sequencing facilitates the discovery of rare mutations that, com-
bined with the continuing unexplained genetic contributions to
complex phenotypes from GWAS (Manolio et al., 2009), has
sparked intense interest in measuring their association with
complex phenotypes. This interest has given rise to a variety of
statistical tests with varying strategies for detecting association
of rare variation with phenotype (Chen et al., 2013; Han and Pan,
2010; Ionita-Laza et al., 2013; Lee et al., 2012a, 2012b; Li and
Leal, 2008; Liu and Leal, 2010; Madsen and Browning, 2009;
Neale et al., 2011; Oualkacha et al., 2013; Price et al., 2010a;
Wu et al., 2011; Zhang et al., 2011). In any single gene, there
are a large number of rare variants due to recent human popula-
tion growth (Coventry et al., 2010; Nelson et al., 2012; Tennessen
et al., 2012), and there may be many nonassociated variants in a
gene. Furthermore, even in large cohorts, there may not be
enough individuals with a given variant to achieve statistical sig-
nificance.
To deal with the aforementioned challenge, all of these types
of tests share the common feature that they group or collapse
rare variation, usually by gene, in order to increase statistical
power (see Wu et al., 2013 for a recent review). Early tests
(such as the cohort allelic sums test [Morgenthaler and Thilly,
2007] and the combined multivariate collapsing method [Li and
Leal, 2008]) assumed that each variant had the same direction
of effect and, in addition, required a fixed minor allele frequency
cutoff to define which variants to include; but these assumptions
are not always valid or optimal. Further innovations have allowed
for weighting of individual variants (for example, by variant fre-
quency in the weighted sum statistic [Madsen and Browning,
2009] or the data [Han and Pan, 2010; Lin and Tang, 2011; Wu
et al., 2011; Zhang et al., 2011]), variants with heterogeneous di-
rection of effect (Han and Pan, 2010; Lin and Tang, 2011; Neale
et al., 2011; Wu et al., 2011; Zhang et al., 2011), and selection of
the ideal frequency cutoff for rare variants (Price et al., 2010a).
Though this remains an active area of research, the SKAT family
of tests (Chen et al., 2013; Ionita-Laza et al., 2013; Lee et al.,
2012a, 2012b; Oualkacha et al., 2013; Wu et al., 2011) has
emerged as one of the most popular. SKAT and its variants allow
for inclusion of covariates for managing both case-control and
quantitative data and family or unrelated data, and they are
computationally undemanding. Although the initial version of
SKAT lost power in cases in which all variants in a gene have
the same direction of effect, the newer SKAT-O (Lee et al.,
2012a) test combines a test handling bidirectional effects and
a test handling unidirectional effects to achieve excellent power
in either case.
Identifying De Novo Mutations
The rarest of variants are de novo mutations: those variants that
arise first in an individual. They have tremendous relevance for
disease biology, as they aremore likely to have functional conse-
quences in rare diseases. Characterizing these mutations also
allows for the estimation of the baseline human mutation rate
as well as its correlation to parental age (Abecasis et al., 2010;
Kong et al., 2012). An entire class of computational tools has
arisen that utilize both sequencing data and pedigree information
to identify de novo mutations genome wide. Most of these tools
currently deal with trios (mother, father, and child) only and can
identify de novo variants arising in the children (Cartwright
et al., 2012; http://sourceforge.net/p/denovogear/wiki/Home/;
Li et al., 2012; Li, 2011). Because sequencing reads have a
higher error rate than traditional genotyping, these tools incorpo-
rate information about coverage, the sequencing error rate, the
expected de novo mutation rate, and family relationships.
Although all of these tools identify potential de novomutations,
there remain significant feature differences between them, and
no single tool has yet emerged as the frontrunner. In addition,
only Samtools, DeNovoGear (DNG), and GATK can also predict
de novo indels. Both DNG and Polymutt can handle larger ped-
igrees, with DNG able to handle multiple siblings and Polymutt
able to handle arbitrarily large pedigrees.
Studying Rare Mendelian Disorders
Rare monogenic disorders have provided unique opportunities
to identify disease genes in humans. Traditionally, such disor-
ders were studied by positional cloning or candidate gene ap-
proaches. Determining their molecular basis, however, was
often hindered by small kindred sizes, genetic heterogeneity,
and diagnostic classifications that may not reflect molecular
pathogenesis. However, high-throughput sequencing of the full
set of protein-coding genes—the exome—helps to overcome
these obstacles by screening thousands of genes in a single
experiment. Although this limits the types of mutations that can
be discovered, rare coding variants that are predicted to have
significant functional consequences can be discovered (Bam-
shad et al., 2011). In fact, it is estimated that, in 60% of pro-
jects, exome sequencing will identify new Mendelian disease
genes (Gilissen et al., 2012), and it is likely this approach also
will contribute to complex disease genetics. Hence, the exome
represents an enriched target space to identify rare variants
with large effect sizes, as opposed to GWAS, wherein variants
have low effect sizes.
The analytical approach applied to most exome sequencing
studies of rare disorders is relatively straightforward. First, ge-netic variants shared by affected individuals (or segregating
with a phenotype, in family studies) are collected. Hundreds or
thousands of variantsmight be in this initial set. These are filtered
using information from public databases (e.g., dbSNP [Sherry
et al., 2001]) to remove common polymorphisms, based on the
expectation that causal mutations will be extremely rare in
human populations. Next, annotation with gene structure infor-
mation and bioinformatics programs (e.g., SIFT, Polyphen,
CONDEL) further restricts the list of candidates to those most
likely to affect an encoded protein. Ideally, these sequential
filtering steps reduce the list to a handful of candidate causal
variants, which can be further evaluated with mutation screening
(in other family members or unrelated, affected individuals),
pathway analysis, and functional validation.
Somatic Variant Detection
The comparison of an individual’s cancer genome to the normal
genome (derived from an unaffected tissue DNA) provides a
comprehensive description of the somatic changes that have
occurred in the transition from normal to cancerous cells. WGS
approaches to somatic variant detection are more challenging
due to the size of the data and the numerous types of variants
that can be discovered by different algorithmic predictors, rela-
tive to exome sequencing. However, structural variants, which
are most difficult to predict accurately and with a reasonable
false positive rate, occur frequently in cancer genomes and
only can be discovered fromWGSdata.With an increasing focus
on characterizing cancer heterogeneity, discussed below, the
ability of somatic variant detection algorithms to predict low-fre-
quency single-nucleotide variants (SNVs) in cancer cell popula-
tions is becoming critically important. There are several new
algorithms with this capability, including Strelka (Saunders
et al., 2012), VarScan 2 (Koboldt et al., 2012), andMuTect (Cibul-
skis et al., 2013). Strelka implements a Bayesian approach that
treats the tumor and normal allele frequencies as continuous var-
iables. In particular, the normal sample is represented as a
mixture of diploid germline variation with noise, and the tumor
samples are represented as a mixture of the normal sample
with somatic variation. This approach is meant to provide robust
call sensitivity on low-purity samples and, as such, provides the
same robust sensitivity for low-level variants. Accuracy around
indel detection is achieved by Strelka by jointly performing indel
search and read realignment in the context of both samples. Var-
Scan 2 is a somatic variation version of the original VarScan al-
gorithm that applies heuristic methods and a statistical test to
detect SNVs and indels and their somatic status by simulta-
neously analyzing the tumor and normal data. In addition,
VarScan 2 can identify both LOH and somatic copy number
alterations as deviations from the log ratio of sequence coverage
depth within the pair that are quantified statistically. MuTect
takes input data from matched tumor and normal DNA align-
ments and removes low-quality sequence data. Variant detec-
tion is performed in the tumor data by a Bayesian classifier, filters
to remove false positives due to sequencing artifacts that are not
captured by the prior error-model-based filters, and designates
variants as somatic or germline using a second Bayesian classi-
fier. The step to remove rare sources of false positives uses a
panel of normal samples filter that represents rare error modes
only detectable from the comparison to additional samples.Cell 155, September 26, 2013 ª2013 Elsevier Inc. 29
Table 1. OMIM Phenotypes for which the Molecular Basis Is
Known, 2007 and 2013
Inheritance Pattern January 2007 July 2013
Autosomal 1,851 3,525
X Linked 169 277
Y Linked 2 4
Mitochondrial 26 28
Total 2,048 3,834Exciting Biological Insights from Recent Studies
Rare Inherited Disorders
Although next-generation sequencing has impacted the human
genetics field as a whole, few areas have benefited more than
the study of rare genetic diseases. Some of the earliest applica-
tions of NGS toMendelian disorders (Table 1) demonstrated that
it was possible to identify disease-causing genes by sequencing
the exomes of a few unrelated individuals (Gilissen et al., 2010;
Hoischen et al., 2010; Lalonde et al., 2010; Ng et al., 2010a,
2010b) or affected family members (Bilgu¨var et al., 2010; Bolze
et al., 2010; Johnson et al., 2010; Krawitz et al., 2010; Musunuru
et al., 2010; Walsh et al., 2010; Wang et al., 2010). Even the
exome sequence of a single index case proved sufficient for
genetic diagnosis for some disorders when information about
the molecular underpinnings of the disease was known. For
example, prioritization of mitochondrial proteins helped to iden-
tify ACAD9 in a case with complex I deficiency (Haack et al.,
2010), whereas prior evidence linking STIM1 to recessive immu-
nodeficiency helped to implicate this gene in a pediatric case
with classic Kaposi sarcoma associated with human herpesvirus
8 infection (Byun et al., 2010).
The impact of NGS technologies on rare genetic diseases is
further evidenced by the growth of the Online Mendelian Inheri-
tance in Man (OMIM) database (McKusick, 2007), in which the
number of inherited phenotypes for which the molecular basis
is known has nearly doubled since 2007 (Table 2). The number
of genes associated with rare diseases, too, has grown at an
impressive rate. Yet for many disorders, elucidation of the ge-
netic basis has outstripped an understanding of the molecular
and pathological mechanisms of disease. More work will be
required to determine the precise relationship between genotype
and phenotype.
Lessons from Mendelian Disease Studies
Although NGS offers a powerful strategy to search for Mendelian
disease genes, it is important to realize that many such studies
fail despite sufficient numbers of samples. One failure occurs
when the causal variant is found but is deemed nonpathogenic.
While the majority of known disease-causing mutations affect
highly conserved protein residues, other pathogenic mecha-
nisms—such as synonymous changes of rare codons that affect
the rate of cotranslational folding (Kimchi-Sarfaty et al., 2007)—
may be responsible but not ascribed importance. This empha-
sizes the need for better functional assays of discovered vari-
ants.
It is also possible to miss a causal variant. Even with NGS and
hybrid capture, 5% of target coding bases do not achieve suf-
ficient coverage for reliable variant detection. Furthermore, with30 Cell 155, September 26, 2013 ª2013 Elsevier Inc.adequate coverage, certain types of mutations (e.g., inversions,
duplications, and other structural variants) remain challenging to
detect. Causal mutations also may reside outside of the regions
targeted for exome sequencing. Nearly half of familial ALS in
Finnish populations, for example, is caused by a hexanucleotide
repeat expansion in the intron of the C9orf72 gene (Renton et al.,
2011).
Failure also can result when one of the underlying assumptions
was incorrect. Genetic and phenotypic heterogeneity can hinder
correct diagnosis of cases, or the assumed mode of inheritance
(and therefore expected genotype pattern) could be incorrect. In
retinitis pigmentosa (RP), for example, around 8.5% of families
provisionally diagnosed with autosomal dominant disease truly
have X-linked RP (Churchill et al., 2013).
In addition, the reliance on public databases such as dbSNP
may confound some analyses of NGS data. The number of
known variants in the human genome has risen dramatically
over the past decade (Figure 1), fueled in large part by the advent
of NGS technologies. Intriguingly, although the submissions
from 2007 to 2012 grew almost exponentially, the number of
unique reference variants (RefSNPs) followed a more linear
growth. Further, a comparison of the global minor allele fre-
quency (GMAF) distribution between dbSNPbuilds 135 (October
2011) and 137 (June 2012) demonstrates that most of the recent
growth came from variants that were rare (GMAF < 0.01) or
extremely rare (GMAF < 0.001) in human populations (Figure 2).
These trends suggest that the majority of common sequence
variants in humans have already been reported, and those that
remain undiscovered tend to be rare, perhaps specific to an
individual or population. This has important implications for
studies of rare genetic diseases. The ponderous size of dbSNP
certainly makes it a powerful discriminatory tool for common
variation. However, it also suggests that dbSNP filtering
approaches must be applied with caution because dbSNP
entries are associated with disease—variants from Online
OMIM (McKusick, 2007) or mutations from the Catalogue of
Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2010,
2011) —and a growing number are too rare to exclude from
consideration.
Sequencing under GWAS Peaks
One way to leverage the results from GWAS and linkage studies
to identify rare variation is to perform targeted sequencing of the
regions identified under significant peaks. This strategy has been
used to identify a rare variant in a gene under a linkage peak
where common SNPs could not explain the variance in the
phenotype (Bowden et al., 2010). In this study, common poly-
morphisms in the ADIPOQ gene that are highly associated with
circulating plasma adiponectin levels in European populations
wereminimally associatedwith plasma adiponectin levels in His-
panic families; however, a rare coding mutation was identified
that contributes up to 17% of the observed variance in Hispanic
plasma adiponectin levels. Additionally, Wang et al. (2013)
sequenced exons of >1,000 genes identified fromGWAS linkage
peaks that impact human stature. Using a pooled sample strat-
egy of individuals whowere significantly shorter than the average
population but were not diagnosed with any known syndrome
affecting height or with any endocrinological deficiency, the re-
searchers identified unique rare nonsynonymous and splicing
Table 2. Disease-Causing Genes Identified by Exome Sequencing Studies, 2009–2010
Gene Disorder Individuals Citation
DHODH Miller syndrome four affected from three kindreds (Ng et al., 2010b)
FLVCR2 Fowler syndrome two unrelated (Lalonde et al., 2010)
GPSM2 Nonsyndromic hearing loss one proband (Walsh et al., 2010)
MLL2 Kabuki syndrome ten unrelated (Ng et al., 2010a)
WDR62 Severe brain malformations one proband (Bilgu¨var et al., 2010)
PIGV Hyperphosphatasia mental retardation three siblings (Krawitz et al., 2010)
WDR35 Sensenbrenner syndrome two unrelated (Gilissen et al., 2010)
STIM1 Kaposi sarcoma one patient (Byun et al., 2010)
ANGPTL3 Familial combined hypolipidemia two family members (Musunuru et al., 2010)
ACAD9 Complex I deficiency one patient (Haack et al., 2010)
SETBP1 Schinzel-Giedion syndrome four unrelated (Hoischen et al., 2010)
TGM6 Spinocerebellar ataxia four family members (Wang et al., 2010)
FADD Autoimmune lymphoproliferative syndrome one proband (Bolze et al., 2010)
VCP Familial ALS two family members (Johnson et al., 2010)mutations. In a similar study design, researchers were able to
narrow a large 288 Kbp region identified from GWAS of multiple
sclerosis to an 86.5 Kbp haplotype block containing 42 SNPs,
using targeted capture and NGS (Cortes et al., 2013).
Family Studies of Complex Disease
There has been a return to family-based experimental designs
for complex disease genetics recently, as it is expected that
many members of the same family will carry a particular rare
variant; hence, the number of individuals needed for rare variant
discovery ismuch smaller than in cohorts of unrelated individuals
(Bailey-Wilson andWilson, 2011). Using a combination of exome
and whole-genome sequencing of affected individuals in
consanguineous families, researchers can use homozygosity
mapping to identify and characterize the variants contributing
to genetically heterogeneous disorders. Nonconsanguineous,
large multigenerational, and multiplex pedigrees can also be
used to identify rare inherited variants. For example, Weedon
et al. (2011) identified a novel heterozygous mutation in
DYNC1H1, segregating in a four-generation family affected
with Charcot-Marie-Tooth disease by using whole-exome
sequencing (WES). Similarly, WES was performed on a three-
generation family with multiple individuals affected with pulmo-
nary arterial hypertension who did not carry the canonical
TGF-b mutation (Austin et al., 2012). WES revealed a frameshift
mutation in caveolin-1 (CAV1) that reduced the normal caveo-
lin-1 in the endothelial cell layer of the small arteries. In many
cases, the variants identified in these studies can also be inde-
pendently validated in other cohorts. For example, WES of a
large pedigree identified a missense mutation in the affected in-
dividuals that also segregated with other families suffering from
late-onset Parkinson disease (Vilarin˜o-Gu¨ell et al., 2011; Zim-
prich et al., 2011), thus bolstering the significance of the associ-
ation. In some studies, WES results provide insights into the
biological pathways involved in disease susceptibility and/or
pathogenicity. For example, Timms et al. (2013) analyzed the
exomes of multiplex families with schizophrenia and identified
rare coding variants in N-methyl-D-aspartate (NMDA) receptor
genes in all of the families. Although the variants were dispersedover many genes, this pathway was significantly enriched for
rare, deleterious mutations and suggested a possible role for
glutamate signaling in the pathogenesis of schizophrenia.
De Novo Mutation Studies
Although genomic research in the past decade has largely
emphasized inherited variation, NGS technologies also allow
us to study, at base-pair resolution, the mutational processes
that occur in humans from one generation to the next. Family-
based WGS studies have shown that each individual’s genome
harbors 74 germline de novo mutations (DNMs) (Conrad
et al., 2011). These mutations are potentially more deleterious
because they have not been subject to natural selection and
therefore are of considerable interest for sporadic diseases.
Neurological and developmental disorders in particular high-
light the impact of DNMs on disease risk. Exome sequencing
revealed rare de novo protein-altering mutations in seven of
ten individuals with idiopathic intellectual disability (ID) affecting
nine different genes (Vissers et al., 2010). Four large-scale
studies (Iossifov et al., 2012; Neale et al., 2012; O’Roak et al.,
2012; Sanders et al., 2012) evaluated the impact of DNMs in
autism spectrum disorder (ASD) via exome sequencing of family
quartets (patient, parents, and an unaffected sibling). Each study
included >100 families and found that DNM rates were consis-
tently higher in patients than in their unaffected siblings. Similar
WES approaches have implicated genes expressed in the devel-
oping heart for sporadic congenital heart disease (Zaidi et al.,
2013) and genes encoding chromatin regulators for sporadic
ALS (Chesi et al., 2013). De novo mutational paradigms have
also been suggested by exome sequencing in sporadic psychi-
atric disorders, such as schizophrenia (Girard et al., 2011; Xu
et al., 2012). These findings collectively support a role for de
novo mutational processes in sporadic disorders and highlight
the extraordinary locus heterogeneity underlying susceptibility
to complex diseases.
The application of NGS to both rare and common genetic
diseases has offered many insights into disease etiology that
undoubtedly merit deeper investigation. Taken together, these
studies have also served to highlight our incompleteCell 155, September 26, 2013 ª2013 Elsevier Inc. 31
Figure 1. Growth in the Numbers of dbSNP
Variants in the Human Genome
Increases in the numbers of SNPs submitted
(dotted line) and cataloged as unique reference
variants (solid line) in dbSNP are charted over the
periodic database releases from August 2002 until
the most recent release in June 2012. As indicated
by the two lines, while overall submissions have
increased exponentially since 2008 (when large
projects such as the 1,000 Genomes Project
began), the number of unique variants has not
increased at a comparable rate.understanding of themolecular mechanisms by whichmutations
cause disease. Nevertheless, it seems likely that applying NGS
to uncover the genetic underpinnings of disease will help us to
better understand the complex relationship between genotype
and phenotype.
Cancer Genomics Discovery
Over the past two years, the growth in cancer genomics discov-
ery due to NGS is unprecedented, with multiple examples of
large-scale WGS- or WES-based studies published in the litera-
ture for both adult and pediatric cancer types. The growth in our
knowledge of the genes frequently mutated in cancer genomes
is illustrated in Figure 3, based on the number of new mutations
deposited in COSMIC (Forbes et al., 2010, 2011). Here, the num-
ber of unique variants identified in tumor genomes stands in
stark contrast to those in germline DNA shown in Figure 1.
Namely, in dbSNP, there is a clear saturation effect because
the majority of variants in any individual genome are shared
with other members of the population (and thus already in
dbSNP). In COSMIC, however, the number of unique variants
closely mirrors the number of mutations submitted, reflecting
the fact that most mutations in a tumor genome are private to
that tumor.
Cancer Genome Heterogeneity
For >100 years, the view of cancer cells through the pathologist’s
microscope has indicated that not all cancer cells in a tissue
block are entirely similar. Several groups, using the digital nature
of NGS data, now have proven this ‘‘heterogeneity’’ of cancer
cells at the genomic level. Initially, genomic heterogeneity was
demonstrated by copy number comparisons between primary
and metastatic disease (Campbell et al., 2010) and by whole-
genome amplification and low-coverage sequencing of ampli-
fied genomic DNA from single breast cancer cells (Navin et al.,
2011). Within the past year, published studies using either
WES or WGS have demonstrated the changes in genomic het-
erogeneity in cancers over the primary-to-relapse/metastatic
transition or have characterized heterogeneity with primary tu-
mor specimens. Specifically, these changes are determined by32 Cell 155, September 26, 2013 ª2013 Elsevier Inc.comparing the associated changes in
the percentage of tumor cells carrying
specific mutations detected by deep
coverage NGS data during disease pro-
gression. These studies evoke an evolu-
tionary aspect to cancer’s response to
survival pressures, including therapy,
and have fueled interest in better under-standing the genomes of patients who are likely to recur in their
disease.
Early in 2012, Ding et al. described changes in heterogeneity
and subclonal architecture of primary acute myeloid leukemia
(AML) samples compared to their matched first relapse samples
for eight patients (Ding et al., 2012). Using WGS coupled with
secondary deep hybrid capture-based NGS data on variant
sites, clusters of mutations defining the genotypes of a founding
clone and derived subclones were identified. In each case stud-
ied, the primary AML sample was either mono- or multiclonal,
whereas the relapse sample was monoclonal and carried the
somatic profile of one of the primary subclones, as well as new
mutations that were acquired during chemotherapy. An analysis
of transversion and transition mutations indicated that all types
of transversions were elevated in the relapse samples, a DNA
damage phenomenon that is attributable to the use of DNA-
damaging chemotherapy agents.
In genomic analyses of renal cell cancers, Gerlinger and col-
leagues (Gerlinger et al., 2012) studied regional heterogeneity
in four advanced tumors and metastases from a clinical trial of
everolimus (an inhibitor of mTOR) to evaluate the similarities
and differences in the genomic landscapes. Their approach
includedWES, SNP arrays, and gene expression arrays. Their re-
sults indicated a branching evolution of the primary andmetasta-
tic tumors studied, with a combination of universally shared and
primary region-specific ormetastasis-specific privatemutations.
Unlike the previous study, everolimus was shown to not impact
the number and types of new mutations in posttreatment sam-
ples studied. A case was made for phenotypic convergent evo-
lution due to spatially separated, distinct mutations in SETD2,
KDM5C, and PTEN.
A study in breast cancer heterogeneity utilized data from 20
breast cancers selected across the differentmolecular subtypes,
one of which was sequenced to 188-fold depth to provide suffi-
cient sensitivity for heterogeneity analysis (Nik-Zainal et al.,
2012). Much like the AML study mentioned above, clustering of
mutations sharing similar variant fractions from high-coverage
Figure 2. dbSNPGrowth due toRare Variant
Discovery
This graphic illustrates the amount of rare and
extremely rare variant discovery in two recent re-
leases of the NCBI dbSNP database, where a
global minor allele frequency of >0.05 is consid-
ered a common variant. As indicated, rare variant
discovery has increased dramatically in the most
recent build of dbSNP (137).data was performed to identify the subclones. The clusters were
further refinedby application of aBayesianDirichlet process, and
further associations were made to identify a hierarchy of muta-
tional events in the natural history of the cancer’s development.
Prediction of Targeted Therapy/Actionable Mutations
Since the earliest descriptions of specific mutations in EGFR
predicting response to small-molecule inhibitors such as tyro-
sine kinase inhibitors (Lynch et al., 2004; Paez et al., 2004; Pao
et al., 2004), the association of somatic mutations to drug
response has been of increasing interest. The use of NGS tech-
nologies in this regard has several advantages over the original
methods (PCR and Sanger fluorescent sequencing) used to
acquire these data. Namely, the NGS-based inquiries required
for discovering the gene-therapy association can be less
hypothesis driven and examine all genes, the associated cost
to generate the data for each patient sample is both less expen-
sive and more rapidly obtained, and the ability to detect specific
types of mutations such as insertions or deletions of one or
several nucleotides is facilitated by NGS. The first aspect is
important becausemost small-molecule therapies target a range
of mutated proteins, so multiple genes must be tested in each
patient. The second aspect is important because these queries
are now approaching clinical usage wherein identification of
appropriate therapy(ies) must happen in a 2–3 week period to
be applicable to patient care. Lastly, although small insertion/
deletionmutations are rarer than single-nucleotide substitutions,
their impact on the resulting protein may be more profound.
Because Sanger sequencing typically fails to detect these vari-
ants, it is both likely that the frequency of these mutations is
underestimated and certain that their response to therapy is
less well understood as a result.
One downside of the use of targeted small-molecule inhibitors
is that many patients experience an initial complete pathologic
response or at least stable disease but then acquire resistance
to the therapy and progress (Engelman et al., 2007). This phe-
nomenon has mainly been studied at the protein level (Girotti
et al., 2013; Prahallad et al., 2012) or by focused sequencing (Se-
quist et al., 2011). Here, results often demonstrate that the
cellular pathway blockade affected by targeted therapy is cir-Cell 155, Scumvented by new mutations and/or
overexpression either of the targeted
gene or of another gene in the same
pathway. Given these discoveries, it
remains to be demonstrated by deep
NGS or single-cell sequencing of pro-
gression disease biopsies whether the
mutations that enable circumvention of
the blockade are pre-existing in a minorproportion of tumor cells or are new mutations that arise in
response to the pathway blockade.
Circulating Tumor DNA Analysis
Many solid tumors shed cells and/or DNA into the blood stream
at very low levels that are thought to fluctuate with increases or
decreases in the disease burden of the patient. Hence, the ability
to detect these changeswith high sensitivity poses an interesting
and potentially powerful disease-monitoring capability that likely
would complement imaging modalities such as CT or MRI but at
much lower cost and with lower associated morbidities (Diehl
et al., 2005; Diehl et al., 2008; Swisher et al., 2005). In this regard,
several groups have recently published manuscripts describing
the selective capture of circulating tumor cells (CTCs) or the
amplification and sequencing of circulating tumor DNA or RNA.
This so-called ‘‘liquid biopsy’’ approach using plasma can detect
the predominant somatic mutations for that tumor type (Forshew
et al., 2012), or if chromosomal translocations or structural vari-
ants already are known from prior characterization of the cancer
genome, PCR primers can be designed to amplify the tumor-
specific products for NGS and analysis (Dawson et al., 2013;
Leary et al., 2012). Another recently published example of this
type of detection by NGS involved the detection of ovarian or
endometrial cancer by gene-specific assays of PAP test samples
(Kinde et al., 2013).
Noninvasive Prenatal Testing
Asmentioned, clinical use of NGS in cancer diagnosis, therapeu-
tic decision making, and progression monitoring is poised for
introduction. Several large academic centers and a handful of
commercial entities are offering NGS-based assays in the
CLIA-regulated environment. An NGS-based clinical assay that
already has received widespread adoption is noninvasive pre-
natal testing for chromosomal abnormality diagnosis using sam-
ples such asmaternal blood. In 1997, Lo et al. demonstrated that
male sex could be determined from circulating fetal DNA in
maternal plasma and serum samples and that the level of circu-
lating fetal DNA increases with gestational age (Lo et al., 1997).
However, achieving high sensitivity and specificity of fetal geno-
typewas difficult, given the low levels of fetal DNA and the cost of
high-depth sequencing.eptember 26, 2013 ª2013 Elsevier Inc. 33
Figure 3. Growth in COSMIC Database Re-
ports of Identified and Unique Mutations
Increases in the numbers of mutations and unique
variants identified from DNA sequencing of cancer
samples as cataloged in the COSMIC database,
from November 2004 until the most recent release
in July 2013. Note that the numbers of unique
variants identified are increasing at a rate equal to
the numbers of mutations discovered.With the advent of NGS, resolving the whole genome of a fetus
frommaternal blood sources became possible. In 2010, Lo et al.
sequencedmaternal plasma genomic DNA to 653 coverage and
then used the parental SNP genotypes (from SNP array data) to
distinguish fetal versus maternal sequencing reads (Lo et al.,
2010). This elegant proof-of-concept study demonstrated that
the entire fetal genome is represented in the maternal plasma.
Yet, this approach was limited by the use of a chorionic villus
sample and the somewhat circular logic by which parental hap-
lotypes were inferred from common heterozygous SNP geno-
types and then used to predict the fetal haplotype, thereby
missing a large proportion of the rare variation. In addition, the
authors were unable to detect de novo mutations. To overcome
these obstacles, Kitzman et al. used WGS with maternal plasma
as well as fosmid clone pooling to resolve long haplotype blocks
in the mother (i.e., ‘‘phasing’’; Kitzman et al., 2012). The paternal
genome was sequenced but not phased. This approach
achieved >99% genotype accuracy at maternal heterozygous
sites when predicting the fetal genotype. In addition, de novo
mutations and recombination switch breakpoints were detected
using a Hidden Markov model. The results were confirmed by
WGS from cord blood after birth. Similarly, Fan et al. (2012) per-
formed WGS and WES with maternal plasma and maternal
haplotype resolution via direct deterministic phasing using single
cells. The paternal genome was inferred using detection of
paternal-specific alleles and imputation, and the fetal genome
was resolved to >99% accuracy using molecular counting of
parental genotypes in the maternal plasma.
These studies demonstrate the feasibility of prenatal testing at
single-nucleotide resolution, but major limitations likely will hind-
er clinical translation. For example, sequencing to sufficient
depth to detect fetal DNA genotypes is still quite expensive. In
addition, it is prohibitively expensive and time consuming to
routinely create and sequence maternal fosmid pools. As sin-
gle-molecule sequencing technologies improve, it may be real-
istic to routinely resolve extended parental haplotypes to assist34 Cell 155, September 26, 2013 ª2013 Elsevier Inc.in fetal genotyping. For the time being,
commercial noninvasive NGS prenatal
tests are offered, but these only detect
common chromosomal aneuploidies
such as Trisomy 21.
Concluding Remarks
In summary, next-generation sequencing
technologies have had an incredible
impact on our knowledge of human ge-
netic diseases over a very short time
frame. Whether this trend will continuerests on a variety of issues, some quite complex. For example,
the size of whole-human-genome data sets remains large, and
this poses significant challenges for data download and storage
and for computational infrastructure. Data privacy of human sub-
jects is paramount but is increasingly difficult to control, raising
concerns in the public that may inhibit consent by individuals
to participate in genetic studies. Ethical aspects overshadow
the return of information to study participants and individuals
seeking genetic diagnosis due to our remaining ignorance about
the pathologic and functional consequences of variation in the
human genome. The next few years will determine which appli-
cations of NGS are incorporated into the clinical diagnostic
setting, many of which may benefit patients but yet may not be
covered by insurers. Even as this scenario plays out, it is un-
doubtedly the case that NGS will continue to be a revolutionary
force in basic biomedical and biological genomics inquiry for
some time to come.
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